CPXVF News Alert Cap-Ex Iron Ore Ltd (CPXVF) 0.0066 09/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cap-Ex Iron Ore Ltd (CPXVF) 0.0066 $CPXVF

ZOU, Curse of Detractors [opinion]
by Tafataona Mahoso - All Africa Global Media - Fri Jan 17, 3:04AM CST
IN my January 12, 2014 instalment in The Sunday Mail, I pointed out the significance of NSSA and ARDA as public entities which survived ESAP and illegal sanctions and were therefore going to play pivotal roles in Zim-Asset.If one looks at the higher education sector, it is also easy to identify the Zimbabwe Open University and the polytechnics and technical colleges as holding the best prospects for enhancing the education and training requirements of Zim-Asset because of their proven record of accessibility to the general population, their flexibility and their proven resilience in times of economic adversity.

Cap-Ex Appoints New CFO and Corporate Secretary
Marketwire - Wed Jul 10, 1:48PM CDT
Cap-Ex Iron Ore Ltd (TSX VENTURE: CEV)(OTCQX: CPXVF)(FRANKFURT: X0V) ("Cap-Ex" or the "Company" is pleased to announce the appointment of Martin Burian, CA, CBV as Chief Financial Officer and Jasvir Kaloti as Corporate Secretary of the Company.

Cap-Ex Releases Positive Preliminary Economic Assessment
Marketwire - Thu Jun 27, 4:01AM CDT
Cap-Ex Iron Ore Ltd (TSX VENTURE: CEV) (FRANKFURT: X0V) (OTCQX: CPXVF) ("Cap-Ex" or the "Company" is pleased to announce that it has received the results of the Preliminary Economic Assessment ("PEA" on the Block 103 Property in western Labrador. The PEA was completed by BBA Inc. ("BBA" located in Montreal, Quebec, and is effective as of June 27, 2013. The complete NI 43-101 Technical Report will be filed on SEDAR and the Cap-Ex website within 45 days of this news release.

Cap-Ex Enters Agreements to Find Strategic Partners
Marketwire - Wed Jun 19, 7:02AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(FRANKFURT: X0V)(OTCQX: CPXVF) ("Cap-Ex" or the "Company" announces that it has entered into two additional non-exclusive agreements to seek a strategic partner/investor for Cap-Ex's Block 103 project.

Cap-Ex Enters Into Agreement with King & Bay West Management
Marketwire - Wed Jun 05, 7:03AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(FRANKFURT: X0V)(OTCQX: CPXVF) ("Cap-Ex" or the "Company" announces that it has entered into a non-exclusive finder's fee agreement (the "Agreement" with King & Bay West Management Corp., a company wholly owned by Mark Morabito ("King & Bay" or the "Finder" whereby King & Bay is to provide services in finding an interested party or parties who wish to complete equity financing, debt financing, off-take or acquisition agreement (collectively, a "Transaction" with the Company. The finder's fee (the "Fee" , when determined on the closing of a Transaction, is payable in cash.

Cap-Ex Announces New President and CEO
Marketwire - Mon Jun 03, 7:02AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(FRANKFURT: XOV)(OTCQX: CPXVF) ("Cap-Ex" or the "Company" announces changes to its senior officers effective May 31, 2013.

Cap-Ex Closes Non-Brokered Private Placement of $2,073,000
Marketwire - Fri May 24, 8:35PM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(FRANKFURT: XOV)(OTCQX: CPXVF) ("Cap-Ex" or the "Company" announces that it has closed a private placement of 20,730,000 units (the "Units" at a price of $0.10 per Unit for proceeds of $2,073,000. Each Unit is comprised of one common share (the "Shares" and one share purchase warrant (the "Warrants" . Each Warrant entitles the holder to purchase one common share (the "Warrant Shares" of the Company at an exercise price of $0.20 for a period of 24 months from the date of issue.

Cap-Ex Iron Ore Ltd.: Corporate Update
Marketwire - Thu May 02, 7:31AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(OTCQX: CPXVF)(FRANKFURT: XOV) ("Cap-Ex" or the "Company" is pleased to provide an update on changes to its executive team and corporate offices.

Cap-Ex Provides Update on Non-Brokered Private Placement
Marketwire - Mon Apr 15, 6:30AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(OTCQX: CPXVF)(FRANKFURT: XOV) ("Cap-Ex" or the "Company" announces that it has agreed to reprice the brokered private placement ("the Offering" from $0.15 per Unit of Cap-Ex ("the Unit" as previously announced on March 22nd , 2013 to $0.10 per Unit, subject to the approval of the TSX Venture Exchange ("TSXV" . The maximum of $5,000,000 has been reduced to $3,000,000. Each Unit will be comprised of one common share and one common share purchase warrant (a "Warrant" . Each whole Warrant will entitle the holder to purchase one common share of the Company at an exercise price of $0.20 for a period of 24 months from the date of issue. Insiders will subscribe up to a maximum amount of $1.3 million.

Cap-Ex Provides Company Update and Announces Non-Brokered Private Placement
Marketwire - Fri Mar 22, 5:45AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(OTCQX: CPXVF)(FRANKFURT: XOV) ("Cap-Ex" or the "Company" is pleased to announce that with the release of the maiden resource and the metallurgical results on its Block 103 Iron Ore Project in the Labrador Trough, the Company is now actively seeking a strategic partner.

Cap-Ex Files Technical Report for Block 103 Project
Marketwire - Fri Mar 22, 5:00AM CDT
Cap-Ex Iron Ore Ltd. (TSX VENTURE: CEV)(OTCQX: CPXVF)(FRANKFURT: XOV) ("Cap-Ex" or the "Company" is pleased to announce that it has filed a National Instrument 43-101 Technical Report (the "Report" on SEDAR at www.sedar.com. The Report is with respect to Cap-Ex's Mineral Resource Estimate on the Block 103 Iron Ore Project in the Labrador Trough, the results of which were announced in a February 4th, 2013 news release. There are no material differences between the results announced in that news release and the results in the Report.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Insights from the New First Presidency on Global Challenges

Updated Category News Views 218

A Historic Conversation with the First Presidency The recent interview featuring the new First Presidency of The Church of Jesus Christ of Latter-day Saints marks an exciting milestone. Conducted by the talented Jane Clayson Johnson, this unique dialogue sheds light on pressing issues within the Church and broader society. It was their first public discussion, making it a...

Continue Reading
Major Bets on Donald Trump's Election Surge Past $52 Million

Updated Category News Views 119

Significant Bets on Trump's Electoral Success A trader on Polymarket, operating under the alias Fredi9999, alongside four other accounts, has made headlines recently by placing enormous bets on Donald Trump’s electoral prospects. This activity has generated considerable chatter among traders in the market. Tracking Trump's Betting Activity Harry Crane, a statistics...

Continue Reading
FMC Corporation Faces Lawsuit Over Securities Violations

Updated Category News Views 190

FMC Corporation Faces Lawsuit Over Securities Violations Recently, the Gross Law Firm has alerted shareholders of FMC Corporation (NYSE: FMC) regarding significant legal developments. This lawsuit brings attention to serious allegations concerning the company's conduct during a specific class period. Shareholder Engagement and Participation Shareholders who purchased FMC...

Continue Reading
Insider Buying at Optima Health Signals Confidence in Future Growth

Updated Category News Views 132

Insightful Insider Share Purchase at Optima Health Optima Health plc (AIM: OPT), a leading provider of corporate health and wellbeing solutions in the UK, recently announced an important transaction involving one of its key insiders. Joanne Newey, who takes on the role of Group Business Development & Propositions Director and is also a Person Discharging Managerial...

Continue Reading
Outlook Therapeutics Prepares for Upcoming Investor Interaction

Updated Category News Views 78

Outlook Therapeutics Connects with Investors at Upcoming Virtual Event ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related...

Continue Reading